# Sonic Hedgehog (Shh): Morphogen Gradient Signaling, Autoproteolytic Cleavage, and Holoprosencephaly


## Key Takeaways

- Sonic Hedgehog (Shh) is a secreted morphogen crucial for embryonic patterning, requiring autoproteolytic cleavage and dual lipidation (cholesterol and palmitate) for its signaling function.
- Dysregulation of Shh signaling, often due to heterozygous loss-of-function mutations in *SHH*, is the primary cause of holoprosencephaly (HPE3), a severe forebrain malformation.
- Shh signaling is transduced via the canonical pathway involving PTCH1 and SMO, culminating in the activation of GLI transcription factors, with non-canonical pathways also contributing to diverse cellular responses.
- Shh-N establishes morphogen gradients through complex mechanisms including oligomerization, SCUBE2-mediated release, cytoneme transport, and exosome association, despite its membrane-tethered nature.
- Somatic mutations in *SHH* are rare in cancer, but pathway activation is common in medulloblastoma and basal cell carcinoma, leading to the development of SMO inhibitors like vismodegib and sonidegib as therapeutic agents.
- Resistance to Hedgehog pathway inhibitors can arise from secondary mutations in SMO or activation of downstream GLI factors or non-canonical pathways, necessitating combination therapies or alternative drug targets.

---

## Executive Summary & Key Metadata

The *Shh* gene encodes Sonic Hedgehog, a secreted morphogen that governs embryonic patterning, cell fate specification, and tissue homeostasis across metazoans. Its dual role—as a short-range inducer and a long-range gradient morphogen—depends on a complex biosynthetic maturation process involving autoproteolytic cleavage, cholesterol and palmitate modification, and regulated release via specialized membrane microdomains. Dysregulation of Shh signaling underlies a spectrum of congenital malformations, most notably holoprosencephaly (HPE), and contributes to the pathogenesis of medulloblastoma and basal cell carcinoma (BCC) in postnatal life.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | Shh |
| **UniProt Accession** | Q62308 |
| **Representative PDB ID** | 3HO5 |
| **Chromosomal Locus** | Mouse chromosome 5 (5q31.2); Human ortholog: 7q36.3 |
| **Primary Molecular Function** | Morphogen; ligand for PTCH1/PTCH2 receptors; activates GLI transcription factors via SMO |
| **Disease & Pathology Associations** | Holoprosencephaly (HPE3), medulloblastoma, basal cell carcinoma, Gorlin syndrome (via pathway dysregulation) |
| **Protein Length (Precursor)** | 437 amino acids (mouse); 462 (human) |
| **Mature Signaling Form** | N-terminal domain (Shh-N), ~19 kDa, dual-lipid modified |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Synteny

The mouse *Shh* gene maps to chromosome 5 at cytogenetic band 5q31.2, spanning approximately 24.5 kilobases (kb) of genomic DNA (GRCm39: chr5:28,377,417–28,401,850). The human ortholog resides at 7q36.3 (GRCh38: chr7:155,799,980–155,812,463), a region associated with the HPE3 critical interval. The gene exhibits strong evolutionary conservation, with orthologs identified in all bilaterian genomes examined, including *Drosophila melanogaster* (*hh*), *Danio rerio* (*shh*), and *Xenopus laevis* (*xshh*). The genomic organization comprises three exons separated by two introns, with the coding sequence distributed across all three exons. Exon 1 encodes the signal peptide and the N-terminal portion of the mature domain; exon 2 contains the autoproteolytic cleavage site and the majority of the signaling domain; exon 3 encodes the C-terminal intein-like domain.

### 1.2 Promoter Architecture and Regulatory Elements

The *Shh* promoter lacks a canonical TATA box but contains multiple GC-rich regions and binding sites for several developmental transcription factors. Chromatin immunoprecipitation (ChIP) studies have identified conserved binding motifs for:

- **GLI proteins** (GLI1, GLI2, GLI3): mediate transcriptional feedback regulation
- **FOXA2 (HNF3β)**: essential for node and floor plate expression
- **NKX2-1 (TTF-1)**: regulates forebrain ventral patterning
- **PAX6**: represses *Shh* in dorsal neural tube
- **Retinoic acid receptors (RAR/RXR)**: provide positional information along the anteroposterior axis

A critical enhancer element, the **SBE2 (Shh brain enhancer 2)**, located ~600 kb upstream of the transcription start site in humans, drives expression in the ventral forebrain and is required for proper hypothalamic and basal ganglia development. Deletion of SBE2 in mice recapitulates forebrain phenotypes observed in HPE. Additional enhancers include:

- **SBE1**: limb bud posterior mesenchyme (ZPA)
- **SBE3**: notochord and floor plate
- **MFCS1 (mammalian conserved sequence 1)**: gut endoderm
- **ZRS (zone of polarizing activity regulatory sequence)**: located in intron 5 of *LMBR1*, ~1 Mb upstream; controls limb-specific expression

### 1.3 Alternative Splicing and Isoforms

The primary transcript undergoes constitutive splicing to produce a single major mRNA of ~2.6 kb. However, several minor splice variants have been documented:

| **Isoform** | **Splice Event** | **Functional Consequence** |
|---|---|---|
| Shh-001 (canonical) | Full-length, all 3 exons | Precursor protein, 437 aa (mouse) |
| Shh-002 | Exon 2 skipping (partial) | Predicted truncated protein lacking catalytic domain; likely non-functional |
| Shh-003 | Alternative 5' UTR | No change in coding sequence; may affect translational efficiency |
| Shh-004 | Intron 1 retention | Introduces premature stop codon; subject to nonsense-mediated decay |

The predominant isoform in embryonic tissues is Shh-001. Quantitative RT-PCR across mouse embryonic stages (E8.5–E14.5) reveals peak expression in the notochord, floor plate, and limb bud ZPA, with subsequent downregulation in differentiating tissues. [Single-cell RNA sequencing](/knowledge/bioinformatics/single-cell-rna-sequencing-from-bulk-to-resolution) datasets (e.g., Mouse Cell Atlas) confirm expression in a restricted set of progenitor populations, including cerebellar granule neuron precursors (CGNPs) and neural stem cells.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization of the Shh Precursor

The 437-amino-acid (mouse) Shh precursor is organized into three functionally distinct regions:

1. **Signal peptide (residues 1–23)**: Directs co-translational translocation into the endoplasmic reticulum (ER); cleaved by signal peptidase.
2. **Shh-N signaling domain (residues 24–197)**: The biologically active morphogen after proteolytic processing; adopts a cysteine-knot fold.
3. **Shh-C domain (residues 198–437)**: An intein-like autoprocessing domain with cholesterol transferase activity; structurally homologous to bacterial self-splicing inteins.

### 2.2 Autoproteolytic Cleavage Mechanism

The Shh-C domain catalyzes an intramolecular cleavage at a conserved Gly-Cys motif (G196-C197 in mouse). The reaction proceeds through an N→S acyl shift, forming a thioester intermediate at the cysteine residue. This intermediate is then resolved by nucleophilic attack from the 3β-hydroxyl group of cholesterol, resulting in:

- Cleavage of the precursor into Shh-N (residues 24–196) and Shh-C (residues 197–437)
- Covalent attachment of cholesterol to the C-terminus of Shh-N
- Subsequent palmitoylation of the N-terminal cysteine (C24) by Hedgehog acyltransferase (HHAT)

The dual lipidation—cholesterol at the C-terminus and palmitate at the N-terminus—tethers Shh-N to the outer leaflet of the plasma membrane, restricting its free diffusion. Structural studies of the Shh-N domain (PDB: 3HO5) reveal a compact globular fold comprising:

- **Five β-strands** arranged in two antiparallel β-sheets
- **One α-helix** (residues 150–165) that forms part of the receptor-binding interface
- **Three disulfide bonds** (C24-C105, C63-C106, C89-C183) that stabilize the cysteine-knot motif
- **A calcium-binding site** at the interface between β-strands 3 and 4, essential for PTCH1 binding

### 2.3 Receptor-Binding Interfaces

The Shh-N domain interacts with its receptor PTCH1 through two distinct interfaces:

- **Interface 1 (calcium-dependent)**: Involves residues E90, D91, D95, and E127, which coordinate a Ca²⁺ ion. This interface is critical for high-affinity binding (Kd ≈ 1–5 nM) and is disrupted by pathogenic mutations such as D95V and E127A.
- **Interface 2 (lipid-binding groove)**: A hydrophobic groove formed by residues V66, F68, L70, and I72 accommodates the palmitate moiety of Shh-N. Mutations in this groove (e.g., F68S) reduce but do not abolish receptor binding.

The cholesterol moiety, while not directly contacting PTCH1, is required for the formation of multimeric Shh-N complexes that facilitate long-range signaling. Cryo-electron microscopy (cryo-EM) structures of the Shh-PTCH1 complex (PDB: 6N7G) show a 2:1 stoichiometry, with one Shh-N dimer bridging two PTCH1 molecules.

### 2.4 Interactive 3D Visualizer Callout

[Interactive 3D Protein Visualizer: Load Shh (PDB: 3HO5)](/tools/protein-structure-viewer?source=direct&pdbId=3HO5)

The visualizer enables exploration of the Shh-N domain with color-coded secondary structure elements, disulfide bonds, and the calcium-binding site. Users can toggle between cartoon, surface, and electrostatic potential representations, and overlay pathogenic mutation positions (e.g., W117G, D95V) mapped from ClinVar.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Canonical Hedgehog Signaling Cascade

Shh signaling is transduced through a conserved pathway that culminates in the activation of GLI family transcription factors. In the absence of Shh, PTCH1 (a 12-pass transmembrane protein) inhibits the G-protein-coupled receptor Smoothened (SMO) through a mechanism involving the translocation of oxysterols and the phosphorylation of SMO by CK1 and GRK2. This inhibition maintains GLI proteins in a repressor form (GLI3R) via proteolytic processing.

Upon Shh binding to PTCH1:

1. **Receptor internalization**: The Shh-PTCH1 complex is endocytosed and targeted for lysosomal degradation, relieving SMO inhibition.
2. **SMO activation**: SMO translocates to the primary cilium, a microtubule-based organelle essential for Hedgehog signal transduction. SMO phosphorylation at multiple serine/threonine residues by CK1α and GRK2 promotes its ciliary accumulation.
3. **GLI processing switch**: Ciliary SMO promotes the dissociation of GLI proteins (GLI2, GLI3) from SUFU (Suppressor of Fused). Full-length GLI2/GLI3 then translocate to the nucleus, where GLI2 acts primarily as an activator (GLI2A) and GLI3 as a repressor (GLI3R).
4. **Transcriptional output**: GLI activators upregulate target genes including *Gli1*, *Ptch1*, *Hhip*, *Myc*, *Cyclin D1*, and *Bcl-2*, establishing a positive feedback loop.

```mermaid
sequenceDiagram
    participant EC as "Extracellular Space"
    participant PM as "Plasma Membrane"
    participant CI as "Primary Cilium"
    participant CY as "Cytoplasm"
    participant NU as "Nucleus"
    Note over EC,PM: Shh-N (dual-lipidated)
    EC->>PM: Binds PTCH1
    PM->>PM: PTCH1 internalization
    PM->>CI: SMO translocation
    CI->>CY: GLI2/GLI3 release from SUFU
    CY->>NU: GLI2A nuclear import
    NU->>NU: Target gene transcription (Gli1, Ptch1)
    NU->>EC: Secreted feedback inhibitors (HHIP)
```

### 3.2 Non-Canonical Signaling Pathways

Beyond the canonical GLI-dependent cascade, Shh activates several non-canonical pathways:

- **PI3K-AKT signaling**: Shh stimulation of CGNPs activates PI3K via a PTCH1-independent mechanism, promoting cell survival and proliferation. This pathway is hyperactivated in Shh-subtype medulloblastoma.
- **Src family kinases**: Shh binding to PTCH1 recruits and activates Src, which phosphorylates β-catenin and modulates Wnt signaling cross-talk.
- **RhoA/ROCK pathway**: In endothelial cells, Shh promotes angiogenesis through RhoA-dependent cytoskeletal reorganization.
- **AMPK/mTORC1**: Shh regulates cellular metabolism by modulating AMPK activity, linking morphogen signaling to bioenergetic status.

### 3.3 Morphogen Gradient Formation and Transport

The dual lipidation of Shh-N poses a biophysical paradox: how does a membrane-tethered protein diffuse over distances of 100–300 μm to establish a morphogen gradient? Multiple mechanisms contribute:

1. **Hedgehog oligomerization**: Shh-N forms soluble multimeric complexes (12–16 mers) via interactions between cholesterol moieties, allowing release from the membrane.
2. **Scube2-mediated release**: The secreted protein SCUBE2 binds to the cholesterol moiety of Shh-N and facilitates its release from the cell surface in a soluble, active form.
3. **Cytonemes and filopodia**: Long actin-based protrusions transport Shh-N directly to adjacent cells, enabling contact-dependent signaling.
4. **Exosome-associated transport**: Shh-N is incorporated into exosomes released from the basolateral surface of producing cells, allowing long-range dissemination.
5. **Heparan sulfate proteoglycans (HSPGs)**: Extracellular matrix components such as glypicans (GPC3, GPC5) bind Shh-N and modulate its diffusion, stability, and presentation to receptors.

The gradient is further shaped by receptor-mediated clearance: PTCH1 internalization and degradation of Shh-N establishes a sink that sharpens the spatial distribution. Mathematical models of Shh gradient formation (reaction-diffusion with receptor turnover) recapitulate observed concentration profiles in the neural tube, with a decay length of ~50 μm.

### 3.4 Protein-Protein Interaction Networks

STRING analysis (confidence score >0.9) identifies a dense interaction network centered on Shh:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| PTCH1 | Receptor; negative regulator of SMO | Direct binding (Kd ≈ 1–5 nM) |
| PTCH2 | Receptor; partially redundant with PTCH1 | Direct binding |
| SMO | Signal transducer; GPCR | Indirect (via PTCH1) |
| GLI1/GLI2/GLI3 | Transcription factors | Downstream effectors |
| SUFU | Negative regulator of GLI | Indirect (via GLI) |
| HHAT | Palmitoyltransferase | Covalent modification |
| SCUBE2 | Shh release factor | Direct binding |
| CDON/BOC | Co-receptors; enhance signaling | Direct binding |
| GAS1 | Co-receptor; promotes signaling | Direct binding |
| HHIP | Negative feedback inhibitor | Direct binding (sequesters Shh) |
| DISP1 | Required for Shh release | Indirect (cholesterol-dependent) |

BioGRID lists 47 physical interactions for mouse Shh, including 23 high-confidence binary interactions confirmed by multiple experimental methods (co-crystal structure, surface plasmon resonance, co-immunoprecipitation).

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Holoprosencephaly (HPE3)

Heterozygous loss-of-function mutations in *SHH* cause holoprosencephaly type 3 (HPE3, OMIM #142945), the most common structural malformation of the forebrain, with an incidence of 1 in 16,000 live births and 1 in 250 conceptuses. The phenotype spectrum ranges from severe alobar HPE (single brain ventricle, cyclopia) to microform HPE (single maxillary central incisor, hypotelorism).

**Mutation classes identified in HPE3:**

| **Mutation Type** | **Frequency** | **Examples** | **Mechanism** |
|---|---|---|---|
| Missense | ~40% | W117G, D95V, E127A, H140Y | Disrupt folding, receptor binding, or autocleavage |
| Nonsense | ~25% | R154X, Q173X | Truncated protein; nonsense-mediated decay |
| Frameshift | ~20% | c.322delC, c.451dupA | Premature termination |
| Splice-site | ~10% | c.IVS2+1G>A | Exon skipping; aberrant protein |
| Whole-gene deletion | ~5% | 7q36.3 microdeletion | Haploinsufficiency |

**Hotspot residues and structural consequences:**

- **W117G** (exon 2): Located in the core of the Shh-N domain; disrupts hydrophobic packing and causes protein misfolding. This mutation is the most common recurrent missense variant in HPE3, accounting for ~8% of all SHH mutations.
- **D95V** (exon 2): A calcium-coordinating residue in the PTCH1-binding interface. The D95V substitution abolishes calcium binding and reduces receptor affinity by >100-fold.
- **E127A** (exon 2): Also in the calcium-binding site; disrupts the electrostatic complementarity required for PTCH1 interaction.
- **H140Y** (exon 2): Located near the palmitate-binding groove; alters lipid-mediated membrane tethering and reduces signaling range.
- **G196R** (exon 2): Substitution at the P1' position of the autocleavage site; prevents proteolytic processing, trapping the precursor in an inactive form.

### 4.2 Cancer-Associated Mutations

Somatic mutations in *SHH* are rare in cancer, but pathway dysregulation is common:

- **Medulloblastoma (SHH subtype)**: ~30% of medulloblastomas exhibit constitutive Hedgehog pathway activation. While most mutations occur in *PTCH1* (40–50%), *SUFU* (10–15%), or *SMO* (5–10%), activating *SHH* mutations have been identified in a small subset (<1%). These are typically gain-of-function mutations that enhance protein stability or receptor affinity.
- **Basal cell carcinoma (BCC)**: Over 90% of BCCs harbor mutations in Hedgehog pathway genes, predominantly *PTCH1* (inactivating) and *SMO* (activating). *SHH* amplification is observed in ~2% of cases.
- **Gorlin syndrome (NBCCS)**: Germline mutations in *PTCH1* predispose to BCC and medulloblastoma; *SHH* mutations are not causative but pathway activation is universal.

### 4.3 Other Clinical Associations

- **VACTERL association**: Rare *SHH* variants have been reported in patients with vertebral defects, anal atresia, cardiac defects, tracheo-esophageal fistula, renal anomalies, and limb abnormalities.
- **Currarino syndrome**: Caused by *MNX1* mutations, but *SHH* haploinsufficiency can phenocopy sacral agenesis.
- **Schizencephaly**: Case reports link *SHH* mutations to clefts in the cerebral hemispheres.

### 4.4 Genotype-Phenotype Correlations

A meta-analysis of 300 HPE3 families revealed:

- **Missense mutations** in the Shh-N domain are associated with milder phenotypes (microform HPE) compared to truncating mutations.
- **Mutations affecting the autocleavage site** (G196) produce severe alobar HPE, as the uncleaved precursor cannot signal.
- **Mutations in the Shh-C domain** are rare but cause dominant-negative effects by sequestering wild-type Shh-N in inactive heterodimers.
- **Variable penetrance**: Penetrance of HPE3 is incomplete (~50–60%), with asymptomatic carriers in ~30% of families. Modifier loci include *ZIC2*, *SIX3*, and *TGIF1*, which interact genetically with *SHH*.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of Hedgehog Signaling

Several viruses have evolved mechanisms to hijack Hedgehog pathway components:

- **Hepatitis C virus (HCV)**: HCV core protein upregulates *SHH* expression in hepatocytes, promoting liver fibrosis and hepatocellular carcinoma. The mechanism involves NF-κB-mediated transcriptional activation of *SHH*.
- **Human papillomavirus (HPV)**: The E6 oncoprotein stabilizes GLI1 by inhibiting its ubiquitination, leading to constitutive Hedgehog pathway activation in cervical cancer cells. E7 similarly enhances GLI1 transcriptional activity.
- **Kaposi's sarcoma-associated herpesvirus (KSHV)**: The viral G-protein-coupled receptor (vGPCR) constitutively activates SMO-independent Hedgehog signaling, contributing to Kaposi's sarcoma pathogenesis.
- **Merkel cell polyomavirus (MCV)**: The small T antigen activates GLI transcription factors via an AKT-dependent mechanism, promoting Merkel cell carcinoma growth.

### 5.2 Bacterial Effectors

- ***Helicobacter pylori***: The CagA oncoprotein induces *SHH* expression in gastric epithelial cells via NF-κB and STAT3 signaling. This contributes to gastric carcinogenesis and is associated with the intestinal metaplasia phenotype.
- ***Mycobacterium tuberculosis***: Infection of macrophages upregulates *SHH*, which modulates the inflammatory response and promotes granuloma formation.

### 5.3 Parasitic Interactions

- ***[Toxoplasma gondii](/knowledge/parasites/protozoa/toxoplasma-gondii-lifecycle-neurological-infection)***: Infection of neural progenitor cells alters *SHH* signaling, potentially contributing to neurodevelopmental abnormalities observed in congenital [toxoplasmosis](/knowledge/parasites/pet-parasites/toxoplasmosis-feline-transmission-public-health-clinical-management).
- ***Plasmodium falciparum***: Cerebral malaria is associated with dysregulated Hedgehog signaling in the blood-brain barrier, though direct interactions with Shh protein have not been demonstrated.

### 5.4 Immune Evasion Mechanisms

Shh signaling modulates the tumor immune microenvironment:

- **T-cell exclusion**: Hedgehog pathway activation in cancer-associated fibroblasts promotes desmoplasia and T-cell exclusion in pancreatic cancer.
- **Macrophage polarization**: Shh promotes M2 macrophage polarization via GLI-dependent transcription of *ARG1* and *IL10*.
- **PD-L1 regulation**: GLI1 directly binds the *CD274* (PD-L1) promoter, upregulating PD-L1 expression in cancer cells and facilitating immune evasion.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Hedgehog Pathway Inhibitors

| **Drug** | **Target** | **Indication** | **Mechanism** |
|---|---|---|---|
| **Vismodegib (Erivedge)** | SMO | Advanced BCC | Competitive SMO antagonist; binds to the heptahelical transmembrane domain |
| **Soniclegib (Odomzo)** | SMO | Locally advanced BCC | SMO antagonist; higher selectivity for SMO over other GPCRs |
| **Glasdegib (Daurismo)** | SMO | AML (with low-dose cytarabine) | SMO antagonist; inhibits GLI1 transcriptional activity |

### 6.2 Investigational Agents

- **Itraconazole**: An antifungal that inhibits SMO by binding to a distinct site from vismodegib; currently in clinical trials for BCC and medulloblastoma.
- **Robotnikinin**: A small molecule that binds directly to Shh-N and blocks PTCH1 interaction; preclinical development.
- **RU-SKI 43**: An inhibitor of HHAT (Hedgehog acyltransferase), preventing palmitoylation of Shh-N and abrogating signaling.
- **GLI inhibitors (GANT-61, GANT-58)**: Target GLI1/GLI2 transcriptional activity downstream of SMO; useful against SMO-mutant resistant tumors.
- **Arsenic trioxide**: Inhibits GLI2 processing and ciliary accumulation; approved for acute promyelocytic leukemia, repurposed for Hedgehog-driven cancers.
- **Antibody-based therapies**: Anti-Shh-N monoclonal antibodies (e.g., 5E1) neutralize Shh in vitro and in vivo; not yet in clinical trials due to poor tumor penetration.

### 6.3 Resistance Mechanisms

Resistance to SMO inhibitors arises through:

- **SMO secondary mutations** (e.g., D473H, W281C, V321M) that prevent drug binding while preserving signaling activity.
- **GLI2 amplification** or **SUFU loss-of-function**, bypassing SMO dependence.
- **Non-canonical pathway activation** (PI3K-AKT, RAS-MAPK) that sustains tumor growth despite GLI inhibition.

### 6.4 Pharmacogenomic Considerations

- **[CYP3A4](/knowledge/bioinformatics/genes/medical-genetics/cyp3a4-gene-structure-function-pathway)/5 metabolism**: Vismodegib and sonidegib are metabolized by CYP3A4; co-administration with CYP3A4 inhibitors (ketoconazole) increases drug exposure, while inducers (rifampin) reduce efficacy.
- **ABC transporters**: Vismodegib is a substrate of P-glycoprotein (ABCB1) and BCRP (ABCG2); polymorphisms in these transporters affect drug disposition.
- **Germline variants**: Patients with *SHH* mutations and HPE may have altered drug sensitivity; however, no pharmacogenomic guidelines exist for Hedgehog inhibitors.

### 6.5 Gene Therapy Approaches

- **Antisense oligonucleotides (ASOs)**: Targeting *SHH* mRNA in cancers with autocrine Shh signaling; preclinical efficacy in medulloblastoma xenografts.
- **CRISPR-Cas9**: Gene editing to disrupt *SHH* in tumor cells or to correct pathogenic mutations in HPE patient-derived iPSCs; proof-of-concept studies only.
- **Adeno-associated virus (AAV) vectors**: Delivery of *SHH* cDNA to promote tissue regeneration (e.g., myocardial infarction, spinal cord injury); phase I trials ongoing for heart failure.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
|---|---|---|
| NCBI Gene (Mouse) | 20423 | https://www.ncbi.nlm.nih.gov/gene/20423 |
| NCBI Gene (Human) | 6469 | https://www.ncbi.nlm.nih.gov/gene/6469 |
| Ensembl (Mouse) | ENSMUSG00000002608 | https://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000002608 |
| Ensembl (Human) | ENSG00000164690 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164690 |
| UniProt (Mouse) | Q62308 | https://www.uniprot.org/uniprotkb/Q62308 |
| UniProt (Human) | Q15465 | https://www.uniprot.org/uniprotkb/Q15465 |
| RCSB PDB | 3HO5 | https://www.rcsb.org/structure/3HO5 |
| ClinVar | SHH | https://www.ncbi.nlm.nih.gov/clinvar/?term=SHH%5Bgene%5D |
| OMIM | 600725 (SHH), 142945 (HPE3) | https://www.omim.org/entry/600725 |
| Gene Ontology (GO) | GO:0005113 (SHH binding), GO:0007224 (smoothened signaling), GO:0030177 (positive regulation of Wnt signaling) | https://www.ebi.ac.uk/QuickGO/ |
| STRING | 20423 (mouse) | https://string-db.org/network/10090.ENSMUSP00000002708 |
| BioGRID | 112345 | https://thebiogrid.org/ |
| Mouse Genome Informatics (MGI) | MGI:98297 | https://www.informatics.jax.org/marker/MGI:98297 |
| Reactome | R-MMU-5358346 (Hedgehog ligand biogenesis) | https://reactome.org/ |
| KEGG Pathway | mmu04340 (Hedgehog signaling) | https://www.genome.jp/kegg/pathway/mmu04340 |

---

## Related Clinical & Scientific Guides

* [GFP (Green Fluorescent Protein): Beta-Barrel Chromophore Physics, Fluorophore Engineering, and Live-Cell Imaging](/knowledge/bioinformatics/genes/model-organisms/gfp-gene-structure-function-pathway)
* [cdc28 (CDK1): Master Cyclin-Dependent Kinase of Cell Cycle Transitions and Cell Division Control](/knowledge/bioinformatics/genes/model-organisms/cdc28-gene-structure-function-pathway)
* [HoxA9 Homeobox: Homeodomain DNA-Binding Architecture, Body Axis Patterning, and Leukemic Transformation](/knowledge/bioinformatics/genes/model-organisms/hoxa9-gene-structure-function-pathway)


## References

[1] Porter JA, Young KE, Beachy PA. Cholesterol modification of hedgehog signaling proteins in animal development. *Science*. 1996;274(5285):255-259. doi:10.1126/science.274.5285.255

[2] Pepinsky RB, Zeng C, Wen D, et al. Identification of a palmitic acid-modified form of human Sonic hedgehog. *J Biol Chem*. 1998;273(22):14037-14045. doi:10.1074/jbc.273.22.14037

[3] Roelink H, Augsburger A, Heemskerk J, et al. Floor plate and motor neuron induction by vhh-1, a vertebrate homolog of hedgehog expressed by the notochord. *Cell*. 1994;76(4):761-775. doi:10.1016/0092-8674(94)90514-2

[4] Chiang C, Litingtung Y, Lee E, et al. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. *Nature*. 1996;383(6599):407-413. doi:10.1038/383407a0

[5] Belloni E, Muenke M, Roessler E, et al. Identification of Sonic hedgehog as a candidate gene responsible for holoprosencephaly. *Nat Genet*. 1996;14(3):353-356. doi:10.1038/ng1196-353

[6] Roessler E, Belloni E, Gaudenz K, et al. Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. *Nat Genet*. 1996;14(3):357-360. doi:10.1038/ng1196-357

[7] Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. *Genes Dev*. 2002;16(21):2743-2748. doi:10.1101/gad.1025302

[8] Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. *Nature*. 2000;406(6799):1005-1009. doi:10.1038/35023008

[9] Bishop B, Aricescu AR, Harlos K, O'Callaghan CA, Jones EY, Siebold C. Structural insights into hedgehog ligand sequestration by the human hedgehog-interacting protein HHIP. *Nat Struct Mol Biol*. 2009;16(7):698-703. doi:10.1038/nsmb.1607

[10] Tukachinsky H, Kuzmickas RP, Jao CY, Liu J, Salic A. Dispatched and scube mediate the efficient secretion of the cholesterol-modified hedgehog ligand. *Cell Rep*. 2016;17(9):2300-2311. doi:10.1016/j.celrep.2016.11.007

[11] Qi X, Schmiege P, Coutavas E, Wang J, Li X. Structures of human Patched and its complex with Sonic hedgehog. *Science*. 2018;361(6406):eaas8935. doi:10.1126/science.aas8935

[12] Gong X, Qian H, Cao P, et al. Structural basis for the recognition of Sonic Hedgehog by human Patched1. *Science*. 2018;361(6406):eaas8936. doi:10.1126/science.aas8936

[13] Kogerman P, Grimm T, Kogerman L, et al. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of GLI-1. *Nat Cell Biol*. 1999;1(5):312-319. doi:10.1038/13031

[14] Sasaki H, Nishizaki Y, Hui C, Nakafuku M, Kondoh H. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. *Development*. 1999;126(17):3915-3924. doi:10.1242/dev.126.17.3915

[15] Corbit KC, Aanstad P, Singla V, Norman AR, Stainier DY, Reiter JF. Vertebrate Smoothened functions at the primary cilium. *Nature*. 2005;437(7061):1018-1021. doi:10.1038/nature04117

[16] Rohatgi R, Milenkovic L, Scott MP. Patched1 regulates hedgehog signaling at the primary cilium. *Science*. 2007;317(5836):372-376. doi:10.1126/science.1139740

[17] Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. *Genes Dev*. 2008;22(18):2454-2472. doi:10.1101/gad.1693608

[18] Ingham PW, Nakano Y, Seger C. Mechanisms and functions of Hedgehog signalling across the metazoa. *Nat Rev Genet*. 2011;12(6):393-406. doi:10.1038/nrg2984

[19] Briscoe J, Thérond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. *Nat Rev Mol Cell Biol*. 2013;14(7):416-429. doi:10.1038/nrm3598

[20] Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the Sonic Hedgehog signaling pathway: review of smoothened and GLI inhibitors. *Cancers (Basel)*. 2016;8(2):22. doi:10.3390/cancers8020022

[21] Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Engl J Med*. 2012;366(23):2171-2179. doi:10.1056/NEJMoa1113713

[22] Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. *Lancet Oncol*. 2015;16(6):716-728. doi:10.1016/S1470-2045(15)70100-2

[23] Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low-dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. *Leukemia*. 2019;33(2):379-389. doi:10.1038/s41375-018-0312-9

[24] Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. *Cancer Cell*. 2013;23(1):23-34. doi:10.1016/j.ccr.2012.11.002

[25] Stanton BZ, Peng LF, Maloof N, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. *Nat Chem Biol*. 2009;5(3):154-156. doi:10.1038/nchembio.142

[26] Petrova E, Rios-Esteves J, Ouerfelli O, Glickman JF, Resh MD. Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling. *Nat Chem Biol*. 2013;9(4):247-249. doi:10.1038/nchembio.1184

[27] Lauth M, Bergström Å, Shimokawa T, Toftgård R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. *Proc Natl Acad Sci USA*. 2007;104(20):8455-8460. doi:10.1073/pnas.0609699104

[28] Beachy PA, Hymowitz SG, Lazarus RA, Leahy DJ, Siebold C.